References
- Faraco G , MoragaA, MooreJ, AnratherJ, PickelVM, IadecolaC. Circulating endothelin-1 alters critical mechanisms regulating cerebral microcirculation. Hypertension62(4), 759–766 (2013).
- Yanagisawa M , KuriharaH, KimuraSet al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature332(6163), 411–415 (1988).
- Ziv I , FlemingerG, DjaldettiR, AchironA, MelamedE, SokolovskyM. Increased plasma endothelin-1 in acute ischemic stroke. Stroke23(7), 1014–1016 (1992).
- Masaoka H , SuzukiR, HirataY, EmoriT, MarumoF, HirakawaK. Raised plasma endothelin in aneurysmal subarachnoid haemorrhage. Lancet2(8676), 1402 (1989).
- Donatelli M , CollettiI, BucaloML, RussoV, VergaS. Plasma endothelin levels in NIDDM patients with macroangiopathy. Diabetes Res.25(4), 159–164 (1994).
- Ergul S , ParishDC, PuettD, ErgulA. Racial differences in plasma endothelin-1 concentrations in individuals with essential hypertension. Hypertension28(4), 652–655 (1996).
- Wei CM , LermanA, RodehefferRJet al. Endothelin in human congestive heart failure. Circulation89(4), 1580–1586 (1994).
- Ferri C , BelliniC, De AngelisCet al. Circulating endothelin-1 concentrations in patients with chronic hypoxia. J. Clin. Pathol.48(6), 519–524 (1995).
- Kawai N , YamamotoT, YamamotoH, McCarronRM, SpatzM. Functional characterization of endothelin receptors on cultured brain capillary endothelial cells of the rat. Neurochem. Int.31(4), 597–605 (1997).
- Miao L , DaiY, ZhangJ. Mechanism of RhoA/Rho kinase activation in endothelin-1-induced contraction in rabbit basilar artery. Am. J. Physiol. Heart Circ. Physiol.283(3), H983–H989 (2002).
- Faraci FM . Effects of endothelin and vasopressin on cerebral blood vessels. Am. J. Physiol.257(3 Pt 2), H799–H803 (1989).
- Kadel KA , HeistadDD, FaraciFM. Effects of endothelin on blood vessels of the brain and choroid plexus. Brain Res.518(1–2), 78–82 (1990).
- Schneider MP , BoesenEI, PollockDM. Contrasting actions of endothelin ET(A) and ET(B) receptors in cardiovascular disease. Annu. Rev. Pharmacol. Toxicol.47, 731–759 (2007).
- Wolfrum S , DendorferA, RikitakeYet al. Inhibition of Rho-kinase leads to rapid activation of phosphatidylinositol 3-kinase/protein kinase Akt and cardiovascular protection. Arterioscler. Thromb. Vasc. Biol.24(10), 1842–1847 (2004).
- Bellapart J , JonesL, BandesheH, BootsR. Plasma endothelin-1 as screening marker for cerebral vasospasm after subarachnoid hemorrhage. Neurocrit. Care doi:10.1007/s12028-013-9887-1 (2013) (Epub ahead of print).
- Moldes O , SobrinoT, MillanMet al. High serum levels of endothelin-1 predict severe cerebral edema in patients with acute ischemic stroke treated with t-PA. Stroke39(7), 2006–2010 (2008).
- Coucha M , LiW, ErgulA. The effect of endothelin receptor A antagonism on basilar artery endothelium-dependent relaxation after ischemic stroke. Life Sci.91(13–14), 676–680 (2012).
- Zhang RL , ZhangC, ZhangLet al. Synergistic effect of an endothelin type A receptor antagonist, S-0139, with rtPA on the neuroprotection after embolic stroke. Stroke39(10), 2830–2836 (2008).
- Mecca AP , O‘ConnorTE, KatovichMJ, SumnersC. Candesartan pretreatment is cerebroprotective in a rat model of endothelin-1-induced middle cerebral artery occlusion. Exp. Physiol.94(8), 937–946 (2009).
- Macdonald RL , KassellNF, MayerSet al. Clazosentan to overcome neurological ischemia and infarction occurring after subarachnoid hemorrhage (CONSCIOUS-1): randomized, double-blind, placebo-controlled Phase 2 dose-finding trial. Stroke39(11), 3015–3021 (2008).